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Abstract
Background: 1-methylnicotinamide (1-MNA), an endogenous metabolite of nicotinamide, has recently gained
interest due to its anti-inflammatory and anti-thrombotic activities linked to the COX-2/PGI2 pathway. Given the
previously reported anti-metastatic activity of prostacyclin (PGI2), we aimed to assess the effects of 1-MNA and its
structurally related analog, 1,4-dimethylpyridine (1,4-DMP), in the prevention of cancer metastasis.
Methods: All the studies on the anti-tumor and anti-metastatic activity of 1-MNA and 1,4-DMP were conducted
using the model of murine mammary gland cancer (4T1) transplanted either orthotopically or intravenously into
female BALB/c mouse. Additionally, the effect of the investigated molecules on cancer cell-induced angiogenesis
was estimated using the matrigel plug assay utilizing 4T1 cells as a source of pro-angiogenic factors.
Results: Neither 1-MNA nor 1,4-DMP, when given in a monotherapy of metastatic cancer, influenced the growth
of 4T1 primary tumors transplanted orthotopically; however, both compounds tended to inhibit 4T1 metastases
formation in lungs of mice that were orthotopically or intravenously inoculated with 4T1 or 4T1-luc2-tdTomato
cells, respectively. Additionally, while 1-MNA enhanced tumor vasculature formation and markedly increased PGI2
generation, 1,4-DMP did not have such an effect. The anti-metastatic activity of 1-MNA and 1,4-DMP was further
confirmed when both agents were applied with a cytostatic drug in a combined treatment of 4T1 murine
mammary gland cancer what resulted in up to 80 % diminution of lung metastases formation.
Conclusions: The results of the studies presented below indicate that 1-MNA and its structural analog 1,4-DMP
prevent metastasis and might be beneficially implemented into the treatment of metastatic breast cancer to ensure
a comprehensive strategy of metastasis control.
Keywords: 1-methylnicotinaimide chloride, 1,4-dimethylpyridinium chloride, Metastasis, Angiogenesis, Combined
therapy, Breast cancer
Background
1-methylnicotinamide (1-MNA), an endogenous metabol-
ite of nicotinamide (NA), is synthetized in the reaction of
nicotinamide N-methyltransferase (NNMT), an enzyme
expressed predominantly in the liver, where it plays a piv-
otal role in the N-methylation of NA and possibly other
pyridine compounds [1]. However, NNMT expression has
also been reported in a number of other types of cells and
organs, including rapidly proliferating cancer cells [2–4]
or the brains of the patients suffering from Parkinson’s
disease [5]. For decades it has been nicotinamide, a
substrate for the NNMT reaction that has attracted at-
tention as a possible therapeutic agent endowed with
pharmacological activities [6–9]. Meanwhile, 1-MNA
has been considered an inactive metabolite [10]. Only
recently has some evidence for the possible therapeutic
application of 1-MNA emerged. The first signals for its
pharmacological potential date back to 2003, when
Gebicki et al. described its anti-inflammatory activity in
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skin disorders such as acne or contact dermatitis [11],
which was further confirmed in an additional study
involving patients with rosacea [12]. In turn, studies by
Chlopicki et al. demonstrated that the mechanisms of
action of 1-MNA involve the activation of PGI2 release
driven by cyclooxygenase 2 (COX-2) [13]. PGI2 releas-
ing capacity of 1-MNA was later shown to afford not
only anti-thrombotic [13] but also fibrinolytic [14], anti-
inflammatory [11, 15] and gastroprotective [16] effects.
Interestingly, 1-MNA did not directly either affect the ac-
tivity of leucocytes [15, 17] or release PGI2 in the perfused
rat hindquarters model [18]. Still, 1-MNA, due to its PGI2
releasing capacity, might serve as a hepatoprotective agent
that protects against concanavalin A induced liver injury
[19] through the downregulation of interleukin-4 (IL-4)
and tumor necrosis factor-α signalization (TNF-α) [20]. In
addition to its anti-platelet, anti-thrombotic and anti-
inflammatory activities, 1-MNA has also been shown to
restore endothelial function in diabetic hypertriglycemic
rats [21], as well as to improve endothelial function in
humans [22].
Given the reports demonstrating that PGI2 displays
anti-metastatic activity [23, 24], and the PGI2 releasing
activity of 1-MNA [13], the potential application of
exogenous 1-MNA to prevent metastatic cancer seems
to be justified. However, currently only limited reports
on the in vivo anti-cancer activity of 1-MNA are avail-
able, including the daily use of 1-MNA in mice bearing
murine leukemia L1210 that resulted in about a 50 %
lifespan increase [25] or the disclosure of the use of 1-
MNA in the prevention of experimental metastases for-
mation [26].
In his patent application Gebicki et al. [26] discloses also
the use of the 1-MNA’s analog, 1,4-dimethylpyridine (1,4-
DMP), another pyridine compound naturally occurring
in roasted coffee seeds. 1,4-DMP is believed to be at
least partially responsible for health-beneficial effects of
coffee and as such has been shown to inhibit thrombus
formation in vivo. As it has been observed for 1-MNA,
the antihrombotic activity of 1,4-DMP depends on the
prostacyclin-related mechanisms [27]. What is more,
results of our preliminary studies have shown that 1,4-
DMP inhibits metastases formation in the model of
spontaneously metastasizing murine mammary gland
cancer (4T1) [28]. Nevertheless, none of the mentioned
reports provide any detailed evidence of the impact re-
vealed by 1-MNA or 1,4-DMP on the growth and me-
tastasis of solid tumors.
Metastasis is a complex process comprising several
discrete steps that result in the formation of secondary
lesions localized at a distance from the primary tumor.
Due to their characteristics, metastases often fail to re-
spond to standard chemotherapy and appear to be in-
accessible for irradiation or surgical treatment. Therefore,
their development usually leads to a dramatic deterior-
ation in survival prognosis, which, in turn, justifies the
common urge for modern therapeutic regimes enabling
the control of metastatic dissemination. Since it is
undeniable that successful metastasis relies on the com-
plex interactions between cancer cells and host body
tissues, one can expect that selective interference with
such an interaction would reduce metastatic potential.
The phenomena occurring in a host body tissues that
have been suggested to beneficially influence cancer
progression comprise, for example, tumor vessel forma-
tion, tumor immune editing and also tumor cell in-
duced platelet aggregation (TCIPA). The latter seems to
be of particular interest, as it not only promotes cancer
metastasis but also increases patients mortality due to car-
diovascular incidents [29]. Nevertheless, platelets un-
doubtedly contribute to metastasis efficiency as they
physically shield migrating cancer cells in the blood-
stream, facilitate immune evasion [30, 31], and promote
cancer cell adhesion to the endothelium of the microvas-
culature in a target tissue [32, 33]. Thus, platelets appear
to be a promising alternative target for metastasis
prevention. Inhibition of metastases development by
anti-platelet pharmacotherapy has been previously
studied, and to date multiple data on the anti-
metastatic potential of anti-platelet agents have been
reported [34–37]. PGI2is the most potent endogenous
anti-platelet agent that, together with its analogs, has been
shown to prevent cancer metastasis [23, 38–42]; however,
the unfavorable short lifetime of the parent molecule and
the hypotensive action of its potent analogs limit their
application.
Given the PGI2-related mechanism of action of 1-MNA
and 1,4-DMP, we decided to investigate whether these
compounds may possess any significant anti-cancer activity
in the model of highly metastatic murine mammary gland
cancer (4T1). The secondary aim of the presented study
was to determine the possibility to utilize both of the com-




1-methylnicotinamide (1-MNA) and 1,4-dimethylpyri-
dinium (1,4-DMP) were used in the form of chlorides
provided by the Lodz University of Technology. Prior
to use, pyridinium salts were diluted in drinking water
such that mice received 100 mg/kg/day of the drug.
Cyclophosphamide (Endoxan) was purchased from
Baxter Oncology GmbH, (Germany). All the drugs
were administrated according to the dosing and ad-
ministration schedules provided in Table 1 and corre-
sponding graphs below.
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Mice
7/8-week-old BALB/c female mice were purchased from
the Center of Experimental Medicine, Medical University
of Bialystok, Poland. 7/8-week-old BALB/c Nude female
mice were provided by Charles Rivers Laboratories
(Germany). All experiments were performed according to
the Interdisciplinary Principles and Guidelines for the Use
of Animals in Research, Marketing and Education
issued by the New York Academy of Sciences’ Ad Hoc
Committee on Animal Research and were approved by
the 1st Local Committee for Experiments with the Use of
Laboratory Animals, Wroclaw, Poland (Table 2).
Cell culture and transplantation
The mouse mammary adenocarcinoma 4T1 cells were
obtained from the American Type Culture Collection
(ATCC, USA). Cells were cultured in RPMI 1640 (IIET,
Poland) with Opti-MEM® (Life Technologies, USA)
(1:1 v/v) medium with 5 % fetal bovine serum (HyClone,
Thermo Fisher Scientific Inc. UK), supplemented with
4.5 g/L glucose, 2 mM glutamine, 1.0 mM sodium
pyruvate (all from Sigma-Aldrich, Germany) and antibi-
otics (penicillin and streptomycin – Polfa Tarchomin,
Poland). The mouse mammary adenocarcinoma 4T1-
luc2-tdTomato cell line stably expressing the firefly
luciferase gene and tdTomato fluorescent protein was
obtained from Caliper Life Sciences Inc. (USA). Cells
were cultured in RPMI 1640 + Gluta-MAX™ medium
(Life Technologies, USA) supplemented with 10 % fetal
bovine serum (Sigma-Aldrich, Germany) and antibiotics
(penicillin and streptomycin – Polfa Tarchomin, Poland).
Both cell line cultures were maintained at 37 °C in a
humidified atmosphere with 5 % CO2.
Irrespective of the tumor model applied prior to the
transplantations, all cells were trypsinized (IIET, Poland),
centrifuged (200 g, 4 °C, 5 min) and counted. For the
model of spontaneous metastasis, 4T1 cells were resus-
pended in Hank’s Balanced Salt Solution (HBSS; IIET,
Poland) such that a suspension of 3 × 105 4T1 cells in
0.05 ml of HBSS was inoculated into the mammary gland
of female BALB/c mice. For the model of experimental
metastasis, 4T1-luc2-tdTomato cells were resuspended in
HBSS such that a suspension of 3 × 105 4T1-luc2-
tdTomato cells in 0.1 ml HBSS was injected into the tail
vein of each female BALB/c Nude mice. For the model of
matrigel plugs, 4T1 cells were resuspended in the mixture
of matrigel (BD Matrigel Basement Matrix High Concen-
tration, Becton, Dickinson and Company, USA) and HBSS
(5:1) such that 1 × 104 cells suspended in 0.3 ml mixture
was injected subcutaneously on the right flank of each
female BALB/c mice.
Estimation of the anti-tumor activity
When tumors became palpable, their maximum length
and width were measured 3 times a week, and the tumor
volume was calculated according to the following formula:
TV ¼ 1
2
 a2  b
Where TV is the tumor volume, a is the shorter diameter
and b is the longer diameter. To compare tumor growth
inhibiting activity between the experimental groups, tumor
Table 1 Drugs, doses and therapeutic regimens applied in the presented studies
Experimental model Drug Route of
administration
Dose Treatment regimen
Experimental metastasis (Fig. 1) 1-MNA Per os in
drinking water
100 mg/kg/day Treatment initiated 7 days prior cancer transplantation
and continued to the end of the experiment
1,4-DMP
Spontaneous metastasis (single
drug treatment) (Fig. 2)
1-MNA Per os in
drinking water
100 mg/kg/day Continuously from the 7th day of the experiment to
the end of the experiment
1,4-DMP
Matrigel plugs (Fig. 3) 1-MNA Per os in
drinking water
100 mg/kg/day Continuously starting from the day of matrigel plugs
transplantation
1,4-DMP
Cyclophosphamide intraperitoneally 25 mg/kg/day On days 0, 3, 5
Spontaneous metastasis (combined
treatment) (Fig. 4 and 5)
1-MNA Per os in
drinking water
100 mg/kg/day Continuously from the 1st day of the experiment to the
end of the experiment
1,4-DMP
Cyclophosphamide Intraperitoneally 25 mg/kg/day From the 7th day of the experiment, 3 times each week
















Matrigel plugs (Fig. 3) 9 36
Spontaneous metastasis
(combined treatment)
(Figs. 4 and 5)
10 50
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Where TGI is the tumor growth inhibition value, TVN
is the mean tumor volume calculated for the studied
experimental group and TVC is the mean tumor volume
calculated for the control group of animals.
Evaluation of the anti-metastatic effect
To determine the anti-metastatic activity of the com-
pounds, the lungs of tumor bearing mice were excised,
weighed and transferred into 5 % solution of buffered
formalin. After tissue fixation, metastatic foci were
counted visually. In the model of experimental metasta-
sis, in vivo visualizations of the metastatic foci localized
in lungs were performed every third day, starting from
the tenth day of the experiment using an In vivo MS
FX PRO system (Carestream Health INC., USA). In
brief, about ten minutes before imaging, D-luciferine
potassium salt (Synchem INC., Germany) was adminis-
tered to each mouse intraperitoneally at the dose of
150 mg/kg. Then, animals were anesthetized with a 3–5 %
(v/v) mixture of isoflurane (Forane, Abbott Laboratories,
USA) in synthetic air (200 ml/min). Anesthesia was
maintained by means of individual masks providing a
1.5–2 % (v/v) mixture of isoflurane and synthetic air.
Visualization was carried out using the following settings:
for X-Ray t = 2 min, f-stop = 5.57, FOV = 198.6; for lu-
minescence capture t = 3 min, binning 2 × 2, f-stop =
5.57, FOV = 198.6. Images were analyzed with Care-
stream MI SE software (Carestream Health INC., USA).
The intensity of the luminescent signal is presented as the
sum intensity of the region of interest and expressed in
arbitrary units [a.u.].
Evaluation of tumor angiogenesis
The influence of 1-MNA and 1,4-DMP on tumor
angiogenesis was evaluated in the model of spontan-
eously metastasizing 4T1 tumors and confirmed in the
model of matrigel plugs. Analyzes were performed by
means of ultrasound imaging of tumor perfusion or im-
munohistochemistry staining of platelet endothelial cell
adhesion molecules (PECAM-1; CD31) in the matrigel
matrix, respectively. For the ultrasound imaging, the
MicroMarker™ Contrast Agent (VisualSonics, Canada)
was prepared according to the manufacturer’s instruc-
tions. Animals were anesthetized with the 3–5 % (v/v)
mixture of isoflurane (Forane, Abbott Laboratories,
USA) in synthetic air (200 ml/min) and placed on an
animal handling station equipped with an individual
mask providing a 1.5–2 % (v/v) mixture of isoflurane
and synthetic air. The position of the handling station was
adjusted so that the central section of the tumor was being
visualized and the contrast agent was injected into the tail
vein of the animal. The signal of the contrast marker accu-
mulating in the tumor mass was recorded using a probe
of 13–24 Mhz frequency (MS250, VisualSonics, Canada).
Next, the wash-in rate was calculated using Vevo LAB
1.7.1. Software (VisualSonics, Ontario, Canada).
Immunohistochemistry was performed in matrigel
plugs (isolated from mice on the 7th day after the
transplantation) which were fixed in buffered formalin
and then cut into 4-μm-thick sections that were subse-
quently dewaxed with xylene and rehydrated in a gradient
of ethanol. For antigen retrieval, sections were heated in a
water bath at 96 °C for 20 min with EnVision™ FLEX Tar-
get Retrieval Solution, High pH (Dako®, Carpinteria,
USA). Endogenous peroxidase activity was quenched in
EnVision™ FLEX Peroxidase-Blocking Reagent for 5 min.
Thereafter, sections were incubated with primary antibody
against PECAM-1 (diluted in 1:50 ratio). Subsequently,
sections were washed in EnVision™ FLEX Wash Buffer
and detection system EnVision™ FLEX/HR SM802 was
added for 30 min at room temperature. The reaction was
developed using 3,3-diaminebezidine tetrahydrochloride
solution (DAB, EnVision™ FLEX DAB+ Chromogen
(DAKO®, Carpinteria, USA). Finally, sections were washed
in distilled water and nuclei were counterstained in
hematoxylin, preparations were dehydrated in an alcohol
gradient and coverslip mounted. Mean vessel density was
evaluated by counting PECAM-1-positive vessels in 5
different fields of view at 200× magnitude.
Platelet activation status
Blood samples from the experimental animals were col-
lected on the last day of the experiments. Samples were
collected into tubes containing 0.05 ml of 5 % ethylenedi-
aminetetraacetic acid (EDTA) solution (Sigma-Aldrich,
Germany). Then, blood plasma was obtained by centrifu-
gation (2000 g, 15 min, 4 °C) and stored at −80 °C until
further analyzed. Prostacyclin generation in the treated
mice was determined by the quantification of plasma 6-
keto-prostaglandin F1α (6-keto-PGF1α) levels. Platelet
activation status was estimated on the basis of thromb-
oxane B2 (TXB2), von Willebrand factor (vWF) and sol-
uble P-selectin plasma concentrations. All analyzes were
conducted using commercial ELISA kits available from
Cusabio Biotech CO., Ltd (Wuhan, China), according to
the manufacturer’s instructions.
E-cadherin/N-cadherin expression in tumor tissue
Protein expression in 4T1 tumor tissue was analyzed
according to the standard Western blot procedure [43].
In brief, samples of tumor tissue collected and immedi-
ately frozen on the last day of the experiments were
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homogenized in RIPA Buffer (Sigma-Aldrich, Germany)
using a FastPrep®-24 MP Bio device (Mp Biomedicals
LLC., USA) with the following settings: CP 24x2, 6 m/s,
40 s. Protein content in all samples was analyzed using
a Bio-Rad Protein Assay (Bio-Rad Laboratories Inc.,
USA) according to the manufacturer’s protocol. Sam-
ples containing 100 μg of protein were separated on the
pre-cast 4–20 % gradient gels (Bio-Rad Laboratories,
Inc., USA) and transferred onto 0.45 μm polyvinylidene
fluoride (PVDF) membranes (Merck Millipore, USA).
Next the membranes were probed with primary rabbit
polyclonal anti-E-cadherin, anti-N-cadherin antibodies
(1:1000, both from Proteintech Group, USA) or rabbit
anti-β-actin (1:1000, Sigma-Aldrich, Germany) anti-
body. Finally, analyzed proteins were detected with sec-
ondary anti-rabbit antibody conjugated with alkaline
phosphatase (ECF Western Blotting Reagent Pack, GE
Healthcare, Great Britain) and the signal was developed
according to manufacturer’s instruction. Blots were
visualized in Image Station 4000MM (Carestream
Healthcare Inc., USA) and analyzed with ImageJ Software,
as follows. The total E-cadherin cellular content compris-
ing mature and unprocessed E-cadherin (with a molecular
weight of approximately 100 and 130 kDa, respectively)
was calculated. Then, E-cadherin and N-cadherin contents
were normalized to β-actin. Finally, E-cadherin to N-
cadherin ratios in individual samples were calculated and
presented as median values.
Systemic toxicity of the anti-cancer treatment
The toxicity of the proposed anti-cancer treatment strat-
egy and its influence on the overall health condition was
estimated on the basis of body weight changes as well as
morphological blood analyzes. The body weight of experi-
mental animals was measured three times each week
throughout the course of all studies. Body weight changes
were calculated using the following formula:
% BW ¼ WN
W 0
 100−100
where: WN is the mean body weight of the animals on
each successive day of the experiment; W0 is the mean
body weight of the animals calculated for day 0 of the
experiment.
Statistical analysis
Data normality was estimated using the Shapiro-Wilk
test with a predetermined p < 0.05 value. The Tukey-
Kramer multiple comparisons test for parametric data
or the Kruskal Walis Test for non-parametric data were
applied; p values lower than 0.05 were considered signifi-
cant. All calculations were performed using STATISTICA
10 (StatSoft Inc., USA) or GraphPad Prism 6 (GraphPad
Software, Inc., USA) software.
Unless stated otherwise all data presented on graphs
correspond to median values ±min/max.
Results
Anti-cancer activity of 1-MNA and 1,4-DMP in a single
drug therapy
To assess the potential ability of 1-MNA and 1,4-DMP
to inhibit metastases formation 4T1-luc2-tdTomato cells
were intravenously inoculated into female BALB/c Nude
mice that were pretreated with 1-MNA or 1,4-DMP for
7 days before transplantation. In vivo visualization of the
metastatic lesions in lungs revealed that administration
of either 1-MNA or 1,4-DMP resulted in delayed onset
of metastatic lesion formation in mice (on the 10th day
of the experiment metastatic lesions were observed in 3
out of 7 treated animals, whereas 5 out of 7 animals were
diagnosed with lung metastases in the control group;
Fig. 1b) and retarded metastases growth as estimated by
means of intravital imaging of the lesions localized in
lungs (Fig. 1a). When compared to the control group of
mice the survival rate among the 1-MNA or 1,4-DMP-
treated animals was increased by approximately 30 % on
the last 22nd day of the experiment (in both of the groups
3 out of 7 animals survived until 22nd day of the experi-
ment, while there were no surviving animals in the control
group, Fig. 1c). Prolonged treatment with 1-MNA and
1,4-DMP did not induce any side effects as during the
whole experiment no symptoms of treatment related tox-
icity was observed (Additional file 1: Figure S1).
Since both 1-MNA and 1,4-DMP, while being well
tolerated and non-toxic, featured anti-metastatic prop-
erties, their anti-cancer activity was further evaluated in
the model of spontaneously metastasizing 4T1 murine
mammary gland cancer. As presented in Fig. 2a, when
administrated from the 7th day of the experiment, none
of the tested compounds influenced the growth kinetics
of 4T1 primary tumors transplanted into syngeneic
BALB/c mice. Despite the lack of the anti-tumor activity,
1,4-DMP inhibited the formation of lung metastases by
about 40 % in comparison to the control (17 vs. 29 median
number of lung metastases, respectively, Fig. 2b). Add-
itionally, the influence of both 1-MNA and 1,4-DMP on
tumor angiogenesis was estimated. The results of the in-
travital ultrasound imaging of blood flow in tumor tissue
reflected in wash-in rate parameter values indicated that
1,4-DMP did not influence tumor blood vessel formation
(Fig. 2c, 2d(III)). 1-MNA, in turn, did not reveal any
marked anti-metastatic activity (Fig. 2b); however, surpris-
ingly it increased the value of the wash-in rate parameter
by 40 % when compared to the control group of animals
(the median value of wash-in rate expressed in arbitrary
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Fig. 1 Anti-metastatic efficacy of 1-MNA and 1,4-DMP in the model of experimental metastasis of 4T1-luc2-tdTomato cells. a Luminescence intensity
of 4T1-luc2-tdTomato cells visualized during intravital imaging of mice treated with 1-MNA and 1,4-DMP (100 mg/kg/day in a drinking water) from the
7th day prior cancer cells intravenous transplantation. Data are presented as mean values ± SD. b Images of luminescence intensity taken on the 10th
day of the experiment for untreated animals (upper row), mice treated with 1-MNA (middle row), mice treated with 1,4-DMP (bottom row). c Kaplan-Meier
survival curves obtained for the animals treated with 1-MNA and 1,4-DMP (days of administration are indicated on the graph with an arrow)
Fig. 2 The influence of 1-MNA and 1,4-DMP on the growth, angiogenesis and metastasis of 4T1 tumors. a Tumor growth kinetics in mice treated
with 1-MNA or 1,4-DMP given at the dose of 100 mg/kg/day in drinking water from the 7th day of the experiment (administration period is
marked on the graph with an arrow). Data are presented as mean values ± SD. b Median number of lung metastases in BALB/c mice bearing 4T1
tumors. Data are presented as raw values with medians. c Wash-in-rate values estimated by the ultrasound imaging of 4T1 tumor blood perfusion
performed on the 25th day of the experiment. Data are presented as median values ±min/max. d Representative images of tumor perfusion taken for:
(I) control group, (II) mice treated with 1-MNA and (III) mice treated with 1,4-DMP
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units [a.u.] was estimated to be 22.1 vs. 13.6, respectively,
Fig. 2c, 2d (II)).
To confirm the pro-angiogenic activity of 1-MNA ob-
served in the model of the spontaneous metastasis of 4T1
tumors, the effect of 1-MNA and 1,4-DMP on tumor
angiogenesis was additionally analyzed in the model of
4T1 cancer-cell induced angiogenesis utilizing matrigel
plugs. Cyclophosphamide given in a metronomic regime
served in this study as a control anti-angiogenic treatment
and proved its efficacy, resulting in about a 30 % lower
mean microvessel density (Fig. 3a and 3b(II)) when com-
pared to the control group (Fig. 3a and 3b(I)) (MVD of 3.5
vs. MVD of 5.1, respectively). Interestingly, 1-MNA
tended to enhance blood vessel formation, as shown by
the median microvessel density in sections obtained on
the 7th day of the experiment (MVD of 7.1, Fig. 3a and
3b(III)), while 1,4-DMP did not influence the angiogenesis
(MVD of 6, Fig. 3a and 3b(IV)). The increased pro-
angiogenic activity of 1-MNA was accompanied by a sig-
nificant increase in 6-keto-PGF1α plasma concentration
(median value of 420.5 pg/ml vs. 145.2 pg/ml in a control
group of animals). Similarly, elevated 6-keto-PGF1α con-
centration was observed in the plasma samples obtained
from mice treated with cyclophosphamide (390.3 pg/ml),
while this was not noted in mice treated with 1,4-DMP
(Fig. 3c). In contrast, in all treated groups reduced TXB2
plasma levels were observed (Fig. 3d), while plasma con-
centrations of vWF and soluble P-selectin were not signifi-
cantly modified by 1-MNA or 1,4-DMP as compared to
control (Fig. 3e–f ).
Anti-cancer activity of 1-MNA and 1,4-DMP in a combined
treatment with cyclophosphamide
Due to the observed effects of 1-MNA and 1,4 DMP on
tumor metastasis and angiogenesis, we next decided to in-
vestigate the influence of both of the compounds on the
anti-cancer efficacy of cyclophosphamide applied in a
metronomic dosage regime. The analysis of the primary
4T1 tumor growth kinetics as well as the weight of the
tumor mass on the last (29th) day of the experiment indi-
cated that both 1-MNA and 1,4-DMP enhanced the ob-
served anti-tumor activity of cyclophosphamide (median
tumor weight in the groups given cyclophosphamide with
1-MNA or 1,4-DMP was estimated as 0.78 g and 0.61 g,
respectively, while the tumor weight in group of mice
treated with cyclophosphamide alone was 1.05 g), which
in the case of the latter resulted in a statistically significant
tumor growth inhibition when compared to the control
group of animals (tumor weight of 1.51 g, Fig. 4a–c). In
contrast, 1-MNA in a combination with cyclophosphamide
Fig. 3 The influence of 1-MNA and 1,4-DMP on tumor angiogenesis estimated in the matrigel plug assay. a Mean microvessel density (MVD)
quantified in matrigel plug sections collected on the 7th day after their implantation and stained with anti-CD31 antibody. Data are presented as
median values ± min/max. b Images of sections stained with anti-CD31 antibody for untreated animals (I), mice treated with cyclophosphamide
(CP) at the dose of 25 mg/kg given intraperitoneally on days 0, 3 and 5 (II), mice treated with 1-MNA (III) and mice treated with 1,4-DMP (IV). Both
1-MNA and 1,4-DMP were given at the dose of 100 mg/kg/day in drinking water, starting from the day of matrigel plug implantation. Plasma levels of:
c 6-keto-PGF1α, d TXB2, e soluble P-selectin, f vWF in mice treated with cyclophosphamide, 1-MNA or 1,4-DMP; all data are presented as median
values ±min/max, dotted lines on the graphs correspond to the value of the median concentration determined for respective agents in healthy
BALB/c mice
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Fig. 4 Anti-cancer efficacy of a combined treatment regime composed of 1-MNA or 1,4-DMP and cyclophosphamide in the 4T1 cancer model.
For ease of interpretation, graphs are presented for the two therapeutic regimes separately. Tumor weight estimated on the 29th day of the
experiment for mice treated with a 1-MNA and cyclophosphamide (CP) or b 1,4-DMP and cyclophosphamide (CP) both presented with
relevant controls; data are presented as median values ± min/max. c Tumor growth inhibition (TGI) values observed for combined therapeutic
regimes presented in reference to TGI of cyclophosphamide alone. In Fig. 4C, days of the drug administrations are indicated with arrows (1-MNA and
1,4-DMP - solid arrow, cyclophosphamide – gray arrows). The number of lung metastases in mice receiving d 1-MNA and cyclophosphamide (CP) or g
1,4-DMP and cyclophosphamide (CP) presented with corresponding controls; data are presented as raw values with medians. TXB2 plasma levels in
mice receiving e 1-MNA and cyclophosphamide (CP) or h 1,4-DMP and cyclophosphamide (CP); data are presented as median values ±min/max. vWF
plasma levels in mice receiving f 1-MNA and cyclophosphamide (CP) or i 1,4-DMP and cyclophosphamide (CP); data are presented as median values
±min/max. j The images of bands obtained in Western blot analysis of tissue samples isolated from the animals assigned to treatment with: (a)
control, (b) cyclophosphamide (CP), (c) 1-MNA, (d) 1-MNA and cyclophosphamide (CP), (e) 1,4-DMP, (f) 1,4-DMP and cyclophosphamide (CP). k
E-cadherin : N-cadherin expression ratios in the samples of tumor tissue collected on the last day of the experiment. The total cellular content
of E-cadherin (comprising protein characterized by the molecular weight of 100 and 130 kDa) and N-cadherin was first normalized to the
content of β-actin and then used to determine E-cadherin to N-cadherin expression ratios that are presented on the graph as median values
with min/max
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retained the anti-metastatic activity of the cytostatic
drug given alone resulting in about a 60 % inhibition of
lung metastases formation (12 vs. 29 median number of
lung metastases in cyclophosphamide and control
group, respectively) (Fig. 4d, 4g). However, when mice
were treated with cyclophosphamide given with 1,4-
DMP, a statistically significant inhibition of lung metas-
tases formation was achieved. The median number of
lung metastases (7 lung metastases) was about 80 %
lower when compared to the control (29 lung metasta-
ses) and about 50 % lower when compared to the group
treated with cyclophosphamide given in a single drug
therapy (12 lung metastases, Fig. 4g). We also observed
that TXB2 plasma level was decreased in those groups
with the least number of identified metastases; however,
vWF concentration remained at a similar level in all
treated animals (Fig. 4e–f and 4h–i).
Interestingly, in tumor tissue isolated from mice
treated with 1-MNA alone or in combination with
cyclophosphamide, a higher E-cadherin expression that
was accompanied with the lower N-cadherin levels was
observed. The estimated E-cadherin to N-cadherin ratio
in the tissue was more than twice as high as in the
control untreated animals. On the other hand, such
phenomena did not occur in mice receiving 1,4-DMP ei-
ther in a single or combined treatment regime (Fig. 4j–k).
Toxicity of the anti-cancer treatment
Neither of the treatments employed influenced the
overall wellbeing of the animals as evidenced by the
weight increase observed throughout the whole experi-
ment (Fig. 5a–b). Therapeutic regimes applied in the
study did not induce any significant changes in blood
morphological parameters that might be attributed to
toxic side effects. No cases of treatment-related deaths
were recorded.
Discussion
Anti-thrombotic, anti-inflammatory, and vasoprotective
properties of 1-MNA ascribed to its contribution to
PGI2 release have been proposed to have therapeutic
significance, for example, in atherosclerosis [44]. On
the other hand, when studied for its anti-metastatic
properties, PGI2, which is the most potent endogenous
inhibitor of platelet aggregation, has proven to be an
efficient metastasis inhibitor [23, 45]. Stable analogs of
PGI2 also displayed anti-cancer activity [38, 40–42].
However, the short lifetime of PGI2 and the side effects
of its analogs when given systemically may limit their
therapeutic application in oncology. Therefore, a PGI2-
releasing agent, such as 1-MNA or its structural analog
1,4-DMP, might become an interesting alternative to the
use of PGI2 in the treatment of metastatic cancer. Here,
we have demonstrated that in the murine model of meta-
static breast cancer 1-MNA and 1,4-DMP both display
anti-metastatic activity, particularly during the vascular
phase of metastasis and if combined with cyclophospha-
mide may ensure an efficient strategy for the prevention
of mammary gland tumor’s metastases formation.
In two separate in vivo studies, both 1-MNA and 1,4-
DMP inhibited to some degree the spontaneous formation
of 4T1 tumor lung metastases while neither of them influ-
enced the growth of 4T1 primary tumors. Moreover, the
observed anti-metastatic effect was strongly related to the
time of therapy initiation, being more pronounced while
1-MNA and 1,4-DMP were administrated from the time
of 4T1 cells orthotopic transplantation. This, in turn, sug-
gests that the activity of both compounds results in the
prevention of early 4T1 tumor’s metastases formation ra-
ther than in any direct influence on established lesions.
Such anti-metastatic activity of 1-MNA and 1,4-DMP was
further confirmed in the model of experimental metastasis
of 4T1-luc2-tdTomato cells that stably express red fluor-
escent protein and the gene for firefly luciferase. In the
Fig. 5 Body weight of BALB/c mice bearing 4T1 tumors, treated with a 1-MNA and cyclophosphamide (CP) or b 1,4-DMP and cyclophosphamide (CP),
both presented with relevant controls. In Fig. 5a-b, days of the drug administrations are indicated with arrows (1-MNA or 1,4-DMP- solid arrow,
cyclophosphamide – gray arrows). Data are presented as mean values ± SD
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study, mice pretreated with either 1-MNA or 1,4-DMP re-
vealed less pronounced metastatic disease characterized
by a delayed onset indicating impaired 4T1 cells homing
in the lungs. Such results remain in agreement with the
previously disclosed anti-metastatic activity of 1-MNA
and 1,4-DMP [26] and other published studies suggesting
that drugs affecting platelet aggregation or endothelial in-
flammation might beneficially influence the vascular stage
of metastatic dissemination, including adhesion of migrat-
ing cancer cells to the vessel wall and subsequent extrava-
sation to the lungs [46, 47].
Possible implementation of 1-MNA and 1,4-DMP in
the therapy of metastatic breast cancer was further con-
firmed when both compounds were administrated with
cyclophosphamide to 4T1 tumor-bearing mice. Inter-
estingly, in the applied tumor model not only did 1-
MNA and 1,4-DMP inhibit lung metastases formation
but also they beneficially influenced the anti-tumor ac-
tivity of the cytostatic drug. Pronounced tumor growth
inhibition in mice receiving the combined treatments
was associated with diminished TXB2 plasma levels sug-
gesting potential involvement of platelet-related mecha-
nisms in the anti-cancer activity of both investigated
molecules. Moreover, when given with cyclophosphamide,
1,4-DMP further improved the anti-metastatic efficacy of
the chemotherapeutic.
Since metastases formation strongly depends on angio-
genesis yield [48], we additionally decided to estimate
the influence of 1-MNA and 1,4-DMP on vessel forma-
tion in either mammary gland tumor mass or matrigel
plugs. The results of the studies revealed surprisingly
distinct effects of 1-MNA and 1,4-DMP on vasculature
development. While 1-MNA stimulated the formation of
blood vessels in both angiogenesis models employed,
1,4-DMP did not affect vasculature formation when
compared to the control group of animals. Such an ob-
servation is not surprising in terms of the proven PGI2-
dependent activity of 1-MNA; however, it might indicate
that either the PGI2 releasing capacity of 1,4-DMP is
lower as compared with 1-MNA, or there is another
anti-metastatic mechanism of action that could be fea-
tured by this compound. Such an assumption is further
supported by the observation that, while both agents
seemed to inhibit platelet activity as manifested by the
reduced plasma level of TXB2, only 1-MNA induced a
profound increase in PGI2 concentration, as reflected in
elevated 6-keto-PGF1α levels. It is known that PGI2 dis-
plays pro-angiogenic activity that has been previously
shown both in vitro and in vivo, in tumor as well as in is-
chemia models [49, 50–52]. In fact, Osawa et al. has
shown that in tumor endothelial cells (TECs) the expres-
sion of the receptor for PGI2 is upregulated, but also that
TECs secrete higher levels of PGI2, which in turn
stimulates angiogenesis in an autocrine manner [52].
Accordingly, we suspect that observed in our study in-
creased capillary formation, induced in response to the
treatment with 1-MNA, resulted from PGI2-releasing
activity of the compound. In case of our studies, how-
ever, such enhanced tumor angiogenesis did not lead to
enhanced tumor growth or metastatic dissemination,
but contrarily to lesser number of diagnosed metastases
and increased efficacy of the applied chemotherapeutic.
Possibly, such effect emerged from the phenomena of
tumor vessels normalization that could occur in re-
sponse to 1-MNA. Such effect is not unparalleled as
the relation between vascular permeability and the drug
transport efficiency into tumors has been previously de-
scribed [53]. Also, Li et al. shows that the prevention of
VEGF-A induced tumor vasculature leakage increase
chemotherapy efficacy and what is even more import-
ant the number of distant metastases [54].
It has been previously described that in order to form
distant metastasis immobile tumor cells undergo epithe-
lial to mesenchymal transition (EMT), a process in
which non-invasive cells loose their epithelial character
and develop mesenchymal features to eventually acquire
more invasive potential. It has been shown that on the
molecular level, EMT is driven by phosphatidylinositol-
3-kinase/Akt (PI3K/Akt) [55] and extracellular signal
regulated kinase 1/2 (ERK1/2) [56] signaling pathways
that when activated contributed to an enhanced metas-
tasis [57]. Activation of PI3K/Akt and ERK1/2 in cancer
cells eventually leads to the down-regulated E-cadherin
and up-regulated N-cadherin expression, among others.
Accordingly, decreased E-cadherin cellular content was
shown to promote cancer cells motility and invasiveness
in vitro and consequently to correlate with worsened
survival prognosis in patients [58, 59]. In our study,
however, enhanced E-cadherin to N-cadherin expression
ratio was observed in mammary gland tumor tissue iso-
lated only from mice treated with 1-MNA or 1-MNA
given with cyclophosphamide. It seems probable that 1-
MNA exerted its anti-metastatic activity on the primary
mammary gland tumor level leading to diminished
metastatic potential of 4T1 cells, while the activity of
1,4-DMP is not directly related to the tumor tissue. Such
observation further supports the idea that 1-MNA and
1,4-DMP affect malignant breast cancer progression in
different manners.
Besides the undeniable beneficial anti-metastatic ac-
tivity of the combined treatment comprising either 1-
MNA or 1,4-DMP and cyclophosphamide, its sustained
low toxicity comparable to that revealed by the cytostatic
drug given alone is probably the most crucial factor from
the clinical point of view. The most undesirable side effect
of a treatment implementing anti-platelet drugs is
bleeding [60–62]. However, in our study we have not
observed any incidence of treatment-related deaths.
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Moreover, the body weight of the treated animals was
constantly increasing throughout the study. This might
be a consequence of the PGI2 releasing activity of the
employed agents. PGI2 has been shown to be a more
potent inhibitor of platelet-platelet interactions than an
inhibitor of platelet adhesion to damaged endothelium
[63]; therefore, it seems to constitute a safe alternative
for other non-selective platelet inhibitors. Moreover,
the recently described beneficial hepatoprotective activ-
ity of 1-MNA and NMMT [64] might suggest its poten-
tial preventive activity also against liver damages
induced by chemotherapy.
On the other hand, recently published data showing an
elevated expression of NMMT in a number of human
tumor types and its possible involvement in proliferation,
tumorogenic capacity and invasiveness of cancer cells
[2, 3, 52, 65] may cause major concerns when consider-
ing implementation of 1-MNA and its analogs into the
anti-cancer therapeutic regimes. Not only NMMT but
also 1-MNA itself was shown to promote cellular
growth what in a study of Parsons et al. resulted in the
prolonged survival and enhanced proliferation of neuro-
bastoma cells in vitro [66]. However, in our preliminary
studies we have established that neither 1-MNA nor 1,4-
DMP promote the proliferation of breast, prostate or
colon cancer cells in vitro, even at the concentrations up
to 1000 μg/ml. On the contrary, we have observed that
while 1-MNA at such concentration did not reveal any
influence on the growth of tested cells, 1,4-DMP actually
inhibited it in 20 % to almost 50 %, depending on the cell
line tested (Additional file 1: Table S1). Additionally, as ev-
idenced by the results presented above neither of studied
pyridine compounds enhanced the growth of 4T1 primary
tumors in vivo. Such discrepancy observed between the
experimental results regarding the activity of NMMT in
tumor cells is not uncommon. For example, while a
number of reports indicate the correlation between the
NMMT expression and the degree of malignancy [65]
other suggest that tumors express high levels of
NMMT that promotes early phase of tumorogenicity,
but has to be down-regulated to enable metastasis. In
fact, these reports attribute NNMT’s high expression to
the prolonged patients’ survival [67–69]. The exact
mechanisms involved in the effects of NNMT in cancer
cells are not entirely clear, however, it is suspected that
they depend on the regulation of the processes based
on the availability of NA and methyl groups [70]. Ac-
cordingly, down-regulation of NMMT was shown to in-
duce apoptosis in human breast cancer cells [3]. It was
reported that 1-MNA might act as NMMT inhibitor
[71] what at least in theory could increase the bioavail-
ability of intracellular NA and thus endure the NMMT
effect leading to the induced apoptosis and chemosensi-
tization of cancer cells [72, 73]. However, in the light of
the results presented here, it seems that a possible dir-
ect effect of 1-MNA on 4T1 murine mammary gland
cells, if any, is neglectable as it did not result in an en-
hanced tumorogenesis or chemoresistance develop-
ment. On the contrary, implementation of 1-MNA and
its analogue 1,4-DMP to the treatment of metastatic
mammary gland cancer has proven beneficial. There-
fore, concerns regarding the use of 1-MNA in the anti-
cancer therapies that may arise on the basis of recently
published NMMT activity in cancer cells seem to be
unjustified as pro-metastatic activity of NNMT seems
to be related to the intracellular methylation status in
cancer cells, while exogenous 1-MNA exerts its anti-
inflammatory and anti-thrombotic properties in circu-
lation and thus indirectly affect cancer cells metastasis.
Conclusions
The results of the studies presented above indicate that 1-
MNA and its analog, 1,4-DMP, might be beneficially im-
plemented into the treatment of metastatic breast cancer
to ensure a more comprehensive strategy of metastasis
control than that based on chemotherapy alone. However,
additional studies should be performed to explain their
mechanism of action in more detail and to establish
whether the observed anti-metastatic activity of both
compounds is restricted only to breast cancer or whether
it is applicable to a broader range of malignant tumors.
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